GlassScriptPhysician profile
Carolina Escobar
NPI 1306047428
$61,926.56
in general payments reported to CMS, 2019-2025
22 companies · $423 in 2025
The $423 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $6,334 · 2021: $387 · 2022: $184 · 2023: $306 · 2024: $803 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134 · Consulting Fee: $300 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.81 |
| Consulting Fee | $300.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $47,409.58 | 2019-2025 | Yescarta |
| Seagen INC. | $12,521.50 | 2019-2020 | |
| Astellas Pharma US INC | $384.42 | 2020-2021 | |
| Abbvie INC. | $354.83 | 2022-2025 | |
| Celgene Corporation | $321.81 | 2024-2025 | Pomalyst, Breyanzi |
| Incyte Corporation | $168.04 | 2021-2025 | Monjuvi, Jakafi |
| Janssen Scientific Affairs, LLC | $130.54 | 2022-2024 | Carvykti |
| Adc Therapeutics America, INC. | $124.92 | 2024 | |
| Jazz Pharmaceuticals INC. | $62.96 | 2022-2023 | |
| Janssen Biotech, INC. | $61.04 | 2025 | Tecvayli, Talvey, Darzalex |
| Genzyme Corporation | $59.60 | 2020-2024 | |
| Karyopharm Therapeutics INC. | $49.89 | 2020-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $41.05 | 2023-2025 | Livtencity |
| Pharmacyclics LLC, An Abbvie Company | $40.74 | 2023 | Epkinly, Imbruvica |
| Novartis Pharmaceuticals Corporation | $40.02 | 2021-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $36.83 | 2022-2024 | Prevymis |
| Alexion Pharmaceuticals, INC. | $23.26 | 2023 | Ultomiris |
| Recordati_rare_diseases_inc. | $21.63 | 2023 | Sylvant |
| Ipsen Biopharmaceuticals, INC | $21.46 | 2023 | Onivyde, Somatuline Depot |
| Amgen INC. | $20.83 | 2020 | |
| Glaxosmithkline, LLC. | $19.57 | 2025 | Blenrep |
| 180 Medical, INC. | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolina Escobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.